Biographical Sketch
Dr. Rose is Director of the Duke Center for Nicotine and Smoking Cessation Research (Duke CNSCR) and Research Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center. Dr. Rose is considered one of the leading authorities on the treatment of nicotine addiction. In the early 1980's, Dr. Rose led the initial studies of transdermal nicotine administration, which helped pave the way for the development of commercial nicotine skin patches as a smoking cessation treatment. Since then, his research program has continued to develop novel smoking cessation treatments and to strive toward a deeper understanding of tobacco dependence. His research is currently applying brain imaging methodologies, including positron emission tomography (PET) and functional magnetic resonance imaging (fMRI), to identify brain substrates underlying craving and addiction. In addition, Dr. Rose's team has worked to develop smoking cessation treatments involving the use of nicotinic antagonists and various substitution strategies to alleviate craving for cigarettes.
Selected Publications
Rose JE, Behm FM, Westman EC, Kukovich P. Pre-cessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine & Tobacco Research, 8:89-101, 2006.
Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology, 16:1-12, 2006.
McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled study. Published online: 2006 Sept. 15 [Epub ahead of print].
Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Corrigall WA, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM. Guidelines for nicotine dose selection for in vivo research. Psychopharmacology, 2006 Aug. 9; [Epub ahead of print].
Marx CE, Trost WT, Shampine L, Behm FM, Giordano LA, Massing MW, Rose JE. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berl.). 186(3):462-472, 2006.
Rose JE. Nicotine replacement therapies and other nicotinic agents. Medication Treatments for Nicotine Dependence. Taylor & Francis LLC-CRC Press, 2006.
McClernon FJ & Rose JE. Mecamylamine moderates cue-induced emotional responses in smokers. Addictive Behaviors, 30, 741-753, 2005.
Rose, JE. Ethics of tobacco company funding. Science, 308(5722), 632, 2005.
Beckham JC, Feldman ME, Mozley SL, Vrana SR, Erkanli A, Clancy CP., & Rose JE. Immediate antecedents of cigarette smoking in smokers with and without posttraumatic stress disorder. Journal of Experimental and Clinical Psychopharmacology, 13, 218-228, 2005.
FJ McClernon, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related fMRI responses to smoking cues. Neuropsychopharmacology, 30:1940-1947, 2005.
Rose JE and Behm FM. Extinguishing the rewarding value of smoke cues: pharmacologic and behavioral treatments. Nicotine and Tobacco Research, 6: 523-532, 2004.
Rose JE, Brauer LH, Behm FM, Cramblett M, Calkins K, and Lawhon D. Psychopharmacologic interactions between nicotine and ethanol. Nicotine and Tobacco Research, 1:133-144, 2004.
Rose JE, Behm FM, Westman EC, Bates JE and Salley A. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacology Biochemistry & Behavior, 76:243-250. 2003.
Rose, JE, Behm, FM, Westman, EC, Mathew RJ, London, ED, Hawk TC, Turkington, TG and Coleman RE. PET Studies of the influences of nicotine on neural systems in cigarette smokers. American Journal of Psychiatry, 160:323-333, 2003.
Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE and Kranzler HR. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcoholism: Clinical and Experimental Research, 26:326-331, 2002.
Rose JE. Evaluation of pharmacologic treatments for smoking cessation. In ED Levin (ed.) Nicotinic Receptors in the Nervous System. Boca Raton, FL: CRC Press, 2001.
Rose JE, Behm FM and Westman EC. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacology Biochemistry & Behavior, 68:187-197, 2001.
Rose JE, Behm FM, Westman, EC, and Johnson M. Dissociating nicotine and non-nicotine components of cigarette smoking. Pharmacology Biochemistry & Behavior, 67:71-81, 2000.
Rose JE, Behm FM, Westman EC, and Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug & Alcohol Dependence, 56:99-107, 1999.
Rose JE, Behm, FM, and Westman EC. Nicotine/mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Experimental and Clinical Psychopharmacology, 6:1-13, 1998.
Rose JE. Nicotine addiction and treatment. Annual Review of Medicine, 47:493-507, 1996.
Westman EC, Behm FM and Rose JE. Airway sensory replacement combined with nicotine replacement for smoking cessation: A randomized, placebo controlled trial using a citric acid inhaler. Chest, 107:1358-1364, 1995.
Behm FM, Schur C, Levin ED, Tashkin DP and Rose JE. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug and Alcohol Dependence, 31;131-138, 1993.
Rose JE, Levin ED, Behm F and Adivi C. Transdermal nicotine facilitates smoking cessation. Clinical Pharmacology and Therapeutics, 30: 323-330, 1990.
Rose JE, Herskovic JE, Trilling Y and Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clinical Pharmacology and Therapeutics, 38:450-456, 1985.